UroGen Pharma (URGN) Return on Capital Employed (2018 - 2026)

UroGen Pharma (URGN) has reported Return on Capital Employed for 9 consecutive years, with 61.33% the latest figure, recorded in Q1 2026.

• Quarterly Return on Capital Employed fell 1328.0% year-over-year to 61.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61.33% (down 1328.0% YoY) and the FY2025 annual result came in at 63.49%, down 1147.0% from the prior year.
• Return on Capital Employed climbed to 61.33% in Q1 2026 per URGN's latest filing, from 85.33% in the prior quarter.
• Over the last five years, Return on Capital Employed for URGN reached as high as 32.32% in Q3 2024 and fell as low as 97.94% in Q2 2023.
• A 5-year average of 61.98% and a median of 61.33% in 2026 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2024 — Return on Capital Employed surged 5944 bps — and 2025, when it tumbled 5395 bps.
• Year by year, Return on Capital Employed stood at 73.1% in 2022, then surged by 42 bps to 42.35% in 2023, then rose by 8 bps to 39.04% in 2024, then tumbled by 119 bps to 85.33% in 2025, then climbed by 28 bps to 61.33% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 61.33%, 85.33%, and 86.27% for Q1 2026, Q4 2025, and Q3 2025 respectively.